These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33868461)

  • 1. Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer.
    Katsuta E; Yan L; Opyrchal M; Kalinski P; Takabe K
    Ther Adv Med Oncol; 2021; 13():17588359211006680. PubMed ID: 33868461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.
    Gao C; Li H; Liu C; Xu X; Zhuang J; Zhou C; Liu L; Feng F; Sun C
    Front Immunol; 2021; 12():650491. PubMed ID: 33968045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in
    Hu ZY; Zheng C; Yang J; Ding S; Tian C; Xie N; Xue L; Wu M; Fu S; Rao Z; Price MA; McCarthy JB; Ouyang Q; Lin J; Deng X
    Front Oncol; 2022; 12():804466. PubMed ID: 35280756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potent potential of MFAP2 in prognosis and immunotherapy of triple-negative breast cancer.
    Huang J; Xu Y; Qi S; Zheng Q; Cui C; Liu L; Liu F
    Discov Oncol; 2024 Jun; 15(1):202. PubMed ID: 38822944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
    Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation Between Immune Cell Infiltration and PD-L1 Expression and Immune-Related lncRNA Determination in Triple-Negative Breast Cancer.
    Yang W; Qiu Z; Zhang J; Zhi X; Yang L; Qiu M; Zhao L; Wang T
    Front Genet; 2022; 13():878658. PubMed ID: 35432487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.
    Wang J; Zhang X; Li J; Ma X; Feng F; Liu L; Wu J; Sun C
    Aging (Albany NY); 2020 Nov; 13(1):351-363. PubMed ID: 33234738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.
    Thomas A; Routh ED; Pullikuth A; Jin G; Su J; Chou JW; Hoadley KA; Print C; Knowlton N; Black MA; Demaria S; Wang E; Bedognetti D; Jones WD; Mehta GA; Gatza ML; Perou CM; Page DB; Triozzi P; Miller LD
    Oncoimmunology; 2018; 7(10):e1490854. PubMed ID: 30386679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
    Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
    Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
    Karn T; Denkert C; Weber KE; Holtrich U; Hanusch C; Sinn BV; Higgs BW; Jank P; Sinn HP; Huober J; Becker C; Blohmer JU; Marmé F; Schmitt WD; Wu S; van Mackelenbergh M; Müller V; Schem C; Stickeler E; Fasching PA; Jackisch C; Untch M; Schneeweiss A; Loibl S
    Ann Oncol; 2020 Sep; 31(9):1216-1222. PubMed ID: 32461104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
    Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of tumor mutation burden and the relationship between tumor mutation burden and immune infiltration in
    Wen Y; Ouyang D; Chen Q; Zeng L; Luo N; He H; Anwar M; Qu L; Zou Q; Yi W
    Gland Surg; 2022 Jan; 11(1):100-114. PubMed ID: 35242673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a CD8
    Dai YW; Wang WM; Zhou X
    Heliyon; 2023 Sep; 9(9):e19798. PubMed ID: 37810147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor mutational burden as a predictor of immunotherapy response in breast cancer.
    O'Meara TA; Tolaney SM
    Oncotarget; 2021 Mar; 12(5):394-400. PubMed ID: 33747355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer.
    Zhou Z; Xie X; Wang X; Zhang X; Li W; Sun T; Cai Y; Wu J; Dang C; Zhang H
    Front Genet; 2021; 12():623424. PubMed ID: 33664769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy.
    Zhao F; Zhao C; Xu T; Lan Y; Lin H; Wu X; Li X
    Front Immunol; 2023; 14():1245514. PubMed ID: 38111587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
    Liu J; Xu W; Li S; Sun R; Cheng W
    Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers.
    O'Meara T; Marczyk M; Qing T; Yaghoobi V; Blenman K; Cole K; Pelekanou V; Rimm DL; Pusztai L
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.